✦ LIBER ✦

Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension

✍ Scribed by Ori Ben-Yehuda; David Pizzuti; Andrea Brown; Marcus Littman; Hunter Gillies; Noreen Henig; Tobias Peschel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Term Outcomes With Ambrisentan Mono

✍ Shannon E. Blalock; Susan Matulevicius; Laura C. Mitchell; Sharon Reimold; John 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 353 KB

Long-Term Pulmonary Hemodynamic Effects

✍ James R. Klinger; Ronald J. Oudiz; Rebecca Spence; Darrin Despain; Christopher D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 399 KB

152 Post-Marketing Hepatic Safety Profil

✍ D.B. Badesch; T. Peschel; D. Pizzuti; H. Gillies; M. Allard; C. Blair; M. Littma 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Long-Term Ambrisentan Therapy for the Tr

✍ Ronald J. Oudiz; Nazzareno Galiè; Horst Olschewski; Fernando Torres; Adaani Fros 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 904 KB

Frequency of Edema in Patients With Pulm

✍ Shelley Shapiro; David M. Pollock; Hunter Gillies; Noreen Henig; Martine Allard; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Clinical safety, pharmacokinetics, and e

✍ Shinichi Takatsuki; Erika B. Rosenzweig; Warren Zuckerman; Daniela Brady; Michel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB